French Society for Biological Psychiatry and Neuropsychopharmacology task force. Formal Consensus for the treatment of Bipolar disorder: An update (2014);Recommandations Formalisées d'Experts de l'Association Française de Psychiatrie Biologique et Neuropsychopharmacologie sur le dépistage et prise en charge du trouble bipolaire: mise à jour 2014

Encephale

Volumn 41, Issue 1, 2015, Pages 93-102

  Samalin, L ^a,b   Guillaume, S ^b,c   Courtet, P ^b,c   Abbar, M ^b,d   Lancrenon, S ^e   Llorca, P M ^a,b  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b CENTRE HOSPITALIER SAINTE ANNE   (France)

^c INSERM U1061   (France)

^d DEPARTMENT OF NEUROLOGY   (France)

^e Sylia Stat   (France)

Author keywords

Bipolar disorder; Guidelines; Pharmacotherapy

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

BIPOLAR DISORDER; CONSENSUS; ERGONOMICS; FRANCE; HUMAN; LONG TERM CARE; MEDICAL SOCIETY; MENTAL PATIENT; PHYSICIAN; PRACTICE GUIDELINE; PSYCHIATRY; PSYCHOPHARMACOLOGY; REVIEW; ACUTE DISEASE; ADULT; CHRONIC DISEASE; CONSENSUS DEVELOPMENT; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED; RISK ASSESSMENT;

ACUTE DISEASE; ADULT; BIOLOGICAL PSYCHIATRY; BIPOLAR DISORDER; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS; RISK ASSESSMENT; SOCIETIES, MEDICAL;

EID: 84923300245     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2014.11.002     Document Type: Article

References (8)

1. Llorca PM, Courtet P, Martin P, et al. Screening and manage-ment of bipolar disorders: results. Encéphale 2010;Suppl. 4:S86-102
2. Samalin L, Llorca PM. Methodological approach tointer guideline variability in the management of bipolardisorders. Encéphale 2012;38(2):126-32
3. Guelfi JD. L'évaluation clinique standardisée en psychiatrie.Tome I. Castres: Éditions médicales Pierre Fabre; 1993
4. Samalin L, Tremey A, Llorca PM. Quetiapine extended releasefor the treatment of bipolar disorder. Expert Rev Neurother2014;6:1-19
5. Wang M, Tong JH, Huang DS, et al. Efficacy of olanzapine mono-therapy for treatment of bipolar I depression: a randomized,double-blind, placebo controlled study. Psychopharmacology(Berl) 2014;231(14):2811-8
6. Citrome L, Ketter TA, Cucchiaro J, et al. Clinical assessmentof lurasidone benefit and risk in the treatment of bipolar Idepression using number needed to treat, number needed toharm, and likelihood to be helped or harmed. J Affect Disord2014;155:20-7
7. Samalin L, Guillaume S, Courtet P, et al. Methodological dif-ferences between pharmacological treatment guidelines forbipolar disorder: what to do for the clinicians? Compr Psychiatry2013;54(4):309-20
8. Samalin L, Nourry A, Charpeaud T, et al. What is the evidence forthe use of second-generation antipsychotic long-acting injec-tables as maintenance treatment in bipolar disorder? Nord JPsychiatry 2014;68(4):227-35.